Global
Excipients for Drug Formulation
Effective solubilization in
Global
Excipients for Drug Formulation
Solubilization of poorly soluble active ingredients
Effective solubilization in solid & liquid dosage forms. The right path for greater solubility and bioavailability.
Poorly soluble drugs are one of the major challenges pharmaceutical manufacturers are facing. More and more drugs in development exhibit low solubility. At BASF, we offer a comprehensive range of cutting-edge solubilization polymers, and have an unparalleled understanding of the corresponding process technologies. This unique combination means that we can make sure you achieve effective solubilization across a range of dosage forms – particularly in solid dispersions.
Furthermore, BASF is a highly successful pioneer in the application of hot-melt extrusion technology in pharmaceutical production, which helps you combine effectiveness with cost efficiency.
Finding the best solubilization solution
Selecting the right solubilization product and technology for a poorly soluble API often involves a lot of trial and error. But partnering with our experts, you can tap into their extensive solubilization expertise and experience with all key technologies, such as hot-melt extrusion, spray drying, and drug layering. Our experts have access to industry-leading tools such as our high-throughput screening (HTS) robot. This puts them in an excellent position to help customers tackle their solubilization and bioavailability challenges rapidly and efficiently.
BASF delivers answers to even the toughest solubilization challenges
- Comprehensive functional portfolio for solubiliation in solid & liquid dosage forms
- Innovative excipients for poorly soluble APIs
- Proven performance and safety
- Technology leader for key technologies such as hot-melt extrusion
- High throughput screening service Solu-HTS
Choose Your Drug Delivery System
Solid dispersions – a great way to increase the solubility and bioavailability of your drug
Liquid dispersions, solutions, emulsions & micro emulsions
Discover our solubilization solutions
Solubilization challenges need new ways
In the Pharmaceutical industry, more than 70% of new drugs developed are poorly water soluble, which means that the human body can hardly adsorb them. This represents one of the major challenges of the industry.
Role of Excipients in Amorphous Solid Dispersions
Dr. Frank Romanski speaks about the the role of excipient selection and key characteristics in amorphous solid dispersions at the BASF Solubilization Symposium in Ludwigshafen, Germany.
Drug Development Challenges
What are key challenges facing the pharmaceutical industry in terms of drug delivery? See Dr. Karl Kolter speaking with Pharmtech about an increasing number of poorly soluble drugs, poor bioavailability and the need for new excipient developments.
Innovation in Solubilization: Quo vadis?
“What cannot be dissolved, cannot be absorbed and cannot cure.” Dr. Karl Kolter from BASF Pharma Solutions spoke about the need of innovation at BASF’s Solubilization Symposium in October. Learn more about what formulators can do to achieve a higher solubility, the future of excipient development we might see down the road and why the Venus de Milo is much more soluble in water than many other pharma actives.
Excipients and Solubilization
There are a lot of excipients on the market – but are there already enough to address current and upcoming formulation challenges? Dr. Ferdinand Brandl about the need of innovation and new developments in the excipients field.
Choosing the right Solubilization Technology
Formulators can choose between many ways to achieve a higher solubility. With different solubilization technologies available, there is no “one size, fits all” solution. Dr. Karl Kolter explains how to decide which technology is most appropriate.
The need for novel surfactants
With different classes of surfactant available for solubilization, there are also further applications beyond solubilization. Dr. Karl Kolter explains possible areas like protein stabilization, antibody formulation or targeting molecules and why there is a need for novel surfactants.
Excipients selection for amorphous solid dispersions
For Dr. Frank Romanski, it is important to understand that solid amorphous dispersions are an “unique and elegant type of system” – the drug is fully solubilized within the polymer matrix. But this makes the right interaction of the API itself in the polymer system critical Learn more on the key features to achieve a stable solid amorphous dispersion.
API Supersaturation and Bioavailability Enhancement
“Supersaturation is a way to get drugs absorbed that would not be absorbed by just looking at their saturation solubility”- Dr. Ferdinand Brandl speaks about keeping your API in supersaturation and why poor solubility of drugs is a problem.
Impact of Matrix Polymers
Take a look at the key matrix polymer properties: In improving the physical stability of systems, you tend to decrease the chemical stability of formulations. Is it possible to strike a good balance in this challenging interplay? Dr. Frank Romanski explains how using more surfactants and solubilizers helps to maintain chemical stability.
Opportunities for early-stage drug development
Being very early in the drug development phase, you have to make decisions in terms of what kind of formulation do you want to go in. As an excipient provider, what we want to offer is options and easy testing methods – Frank Romanski presents opportunities in drug development.
Testing the Functionality of Solubility Approach
The complexity of testing: Is it enough to just analyze how much drug dissolves over time? It works fine for traditional formulations. But with more complex systems like amorphous solid dispersions, a different number of phases are present. Dr. Frank Romanski takes a deep dive together with Pharmtech on ways to test the functionality of solubility approaches.
What causes drug precipitation?
Supersaturating drug delivery systems can enhance bioavailability. However, supersaturating is the driving force of drug precipitation. Dr. Ferdinand Brand explains what causes drug precipitation and why this is a problem – and how formulators should address this issue.
Lipid-Based Drug Delivery Systems
Lipid-Based Drug Delivery Systems are challenging – how do you measure them? And how do you know how much drug is actually coming out? Learn more about drug delivery within these multifaced systems and why its variability affects formulation.
The importance of the structure activity relationship
Precipitation consists of two processes: Nucleation and crystal growth. Polymers can be used to inhibit nucleation and crystal growth rate, but the effectiveness of the polymer depends on the properties of the drug molecules. In this feature with Pharmtech, Dr. Ferdinand Brandl explains what this means for the importance of structure activity relationship.
Preparation Method and Amorphous Systems
The preparation method is crucial in solid amorphous systems. “It really matters how we prepare them – depending on the method we are using, we are landing somewhere else on the energy landscape.” In this feature with Pharmtech, Dr. Thomas Rades from University of Copenhagen explains different preparation methods and their consequences for the stability of amorphous systems.
In Conversation with Andreas Gryczke of BASF
The Medicine Maker's Charlotte Barker sat down with business leaders and specialists from across the pharmaceutical manufacturing landscape to discuss the latest innovations and trends. Here, Charlotte speaks with Andreas Gryczke from BASF.
Amorphous versus Co-Amorphous Systems
Not many people are familiar with Co-Amorphous Systems. What’s the difference to Amorphous Systems? And what are the advantages? Dr. Thomas Rades from University of Copenhagen gives an overview of the benefits in using small molecules instead of another polymer.
Using Lipid-Based Systems to Improve Solubility
Imagine someone is interested in developing a lipid-based drug delivery system. What are the key considerations and requirements? Dr. Annette Muellertz from Copenhagen University takes on this topic – and explains how supersaturating drugs might be interesting to reduce the excipient load.
Testing Lipid-Based Drug Delivery Systems Performance
There seems to be a lack of in-vitro/in-vivo correlation when working with lipid-based drug delivery systems (LBDDS). Dr. Annette Muellertz speaks about how to approach this issue and how you can test the performance of LBDDS.
Optimizing Lipid-based Drug Delivery Systems
Prof. Anette Müllertz, University of Copenhagen, speaks about the influence of drug load and composition when it comes to optimizing lipid-based drug delivery systems at the BASF Solubilization Symposium.
How to keep your API in supersaturation?
Dr. Ferdinand Brandl speaks at the BASF Solubilization Symposium about process of drug precipitation and different ways to inhibit precipitation. He also presents a new crystallization inhibitor from a BASF research project.
Drug Delivery from Multiphase Systems
At the BASF Solubilization Symposium Dr. Frank Romanski speaks about poorly water-soluble drugs, solubilization techniques, lipid complexity and the need for surfactants.
Biorelevant Dissolution Tests
At the BASF Solubilization Symposium Dr. Frank Romanski talks about biorelevant dissolution tests and factors that influence supersaturation and precipitation.
Overcoming Solubility Challenges
In the Thought-Leadership Series on Solubilization with Pharmaceutical Technology Rita Peters and Nigel Langley discuss how to overcome solubility challenges.
Common Formulation Challenges
At the annual Meeting of The American Association of Pharmaceutical Scientists (AAPS) Rita Peters and Nigel Langley talk about solubilization challenges in common formulation.
Facilitating Innovation
At the annual Meeting of The American Association of Pharmaceutical Scientists (AAPS) Rita Peters and Nigel Langley talk about how to facilitate innovation in the pharma industry.
Nano-FTIR as characterization tool for ASD
At the BASF Symposium Dr. Tobias Reinhard Umbach talks about how Nano-FTIR is used as characterization tool for amorphous solid dispersions (ASD).
Stabilizing Amorphous Drugs
Prof. Thomas Rades, University of Copenhagen, talks about polymers and small molecules in the process of stabilizing amorphous drugs at the BASF Solubilization Symposium.
Learn more about our solubilization solutions
eBook
The Formulation Complex: Unravelling the challenges and trends in formulation best practice – and why lipids and softgels are leading the way.
-
1
ebook
Formulation Technologies and Excipient Selection: Strategies for Improving Solubility
-
1
eBook
The Science of Insolubility: Experts come together to discuss the chemistry of solubility – and the solutions of the future
-
1
Webinar
Practical Considerations for Overcoming Bioavailability Challenges with LBDDS ...
Webinar
Choosing the Proper Dissolution Method When Testing Solubilization Performance
Webinar
Twin Screw Wet Granulation for Solubility Enhancement of Poorly Water-Soluble Drugs
Podcast
Twin Screw Wet Granulation for Solubility Enhancement of Poorly Water-Soluble Drugs
Webinar
How glass-forming polymers improve bioavailability / Enhanced oral bioavailability with Soluplus® – case study
The Medicine Maker
From Brick Dust to Blockbuster? - Self-emulsifying lipids, and other innovative solubilizers and polymers
-
1
Drug Development & Delivery
SPECIAL FEATURE - Improving Bioavailability & Solubility: A Top-Down Versus Bottom-Up Approach
-
1
European Journal of Pharmaceutics and Biopharmaceutics
Micro-scale prediction method for API-solubility in polymeric matrices
-
1
Pharmaceutical Technology
The advantages and disadvantages of hot-melt extrusion in solid dispersion formulations
-
1
Drug Development & Delivery
EXCIPIENT UPDATE - Soluplus®: An Understanding of Supersaturation From Amorphous Solid Dispersions
-
1
